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Background: Pregnancy-associated placental protein-A (PAPP-A) is a metalloprotease which circulates as an
hetero-tetramer in maternal blood. Its maternal serum concentration in fetal trisomy 21 is decreased during
the first trimester, so that PAPP-A is a useful screening biomarker. However, the regulation of PAPP-A placental secretion
is unclear. We therefore investigated the secretion of PAPP-A in pregnancies complicated by fetal aneuploidies, both
in vivo and in vitro.
Methods: Maternal serum collected between 10 WG and 33 WG during 7014 normal pregnancies and 96 pregnancies
complicated by fetal trisomy 21, 18, and 13 were assayed for PAPP-A using the Immulite 2000xpi system®.
The pregnancies were monitored using ultrasound scanning, fetal karyotyping and placental analysis. Villous
cytotrophoblasts were isolated from normal and trisomic placenta and cultured to investigate PAPP-A secretion
in vitro (n = 6).
Results: An increased nuchal translucency during the first trimester is a common feature of many chromosomal defect
but each aneuploidy has its own syndromic pattern of abnormalities detectable at the prenatal ultrasound scanning
and confirmed at the fetal examination thereafter. PAPP-A levels rise throughout normal pregnancy whereas in trisomy
21, PAPP-A levels were significantly decreased, but only during the first trimester. PAPP-A levels were decreased in
trisomy 13 and sharply in trisomy 18, whatever the gestational age. In vitro, PAPP-A secretion was decreased in
aneuploidy, and associated with decreased hCG secretion in Trisomy 21 and 18. These biochemical profiles did not
appear to be linked to any specific histological lesions affecting the placenta.
Conclusions: These profiles may reflect different quantitative and qualitative placental dysfunctions in the
context of these aneuploidies.
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Pregnancy-associated placental protein-A (PAPP-A) was
first isolated in the 1970s from the serum of pregnant
women, and the synthesis of PAPP-A mRNA has since
been demonstrated in numerous tissues [1,2]. PAPP-A is a
metalloprotease belonging to the metzincin superfamily of
zinc peptidase. It is active as a homodimer (dPAPP-A)
which cleaves insulin-like growth factor binding proteins 4
and 5, thus regulating local IGF bioavailability and hence
cell differentiation and proliferation [3,4]. dPAPP-A circu-
lates at very low levels in non-pregnant women and men
[5]. This dPAPP-A is abundantly expressed in unstable cor-
onary atherosclerotic plaques and can be released in the
event of rupture, thus rendering dPAPP-A a biomarker for
coronary syndrome and unstable angina [6,7]. In preg-
nancy, PAPP-A is produced at high levels by the placenta
and circulates as a covalent 2:2 heterotetrameric com-
plex (htPAPP-A), designated PAPP-A/proMBP, with the
proform of an eosinophil major basic protein (proMBP)
that inhibits dPAPP-A proteasic activity [8]. Measure-
ment of this complex is of interest in pregnancy [9,10].
Decreased levels are associated with adverse pregnancy
outcomes such as intrauterine growth restriction (IUGR),
preterm delivery, miscarriage and pre-eclampsia [10-12].
The principal routine value of PAPP-A is the prenatal
screening of fetal aneuploidy, particularly for trisomy 21
which is often associated with low PAPP-A levels during
the first trimester of pregnancy [13,14]. However, the
patho-physiological mechanisms underlying this de-
crease are unclear and little is known about PAPP-A
levels during the second and third trimesters of preg-
nancy in the event of fetal aneuploidy. Our aim
was therefore to investigate the placental secretion
of PAPP-A in vivo by characterising maternal levels of
PAPP-A throughout pregnancy in the case of fetal aneu-
ploidy (trisomy 21, trisomy 18 and trisomy 13) in a large
cohort, and in vitro by culturing villous cytotrophoblasts
isolated from aneuploid placentas.
Methods
Maternal serum collection
Maternal blood samples were collected prospectively ac-
cording to the French policy on the screening of prenatal
trisomy 21 at Port Royal Maternity Department Hospital,
which is a reference centre for prenatal screening in Paris.
This type of screening must be offered to every pregnant
woman since 10 WG (weeks of gestation) [15]. Calculat-
ing the risk requires the measurement of nuchal translu-
cency thickness (nt) and maternal serum markers i.e.
pregnancy-associated plasma protein-A (PAPP-A) and
the free β subunit of chorionic gonadotrophin (hCGβ) be-
fore 14WG; after that time point, hCGβ or total hCG and
alphafoetoprotein (AFP) are determined, in combination
with maternal age. The risk of T21was calculated usingthe Immulite 2000 automatic system and Prisca 4 soft-
ware (Siemens® Typolog, Germany) [16]. Additional ma-
ternal blood samples collected at the time of pregnancy
terminations in the cases of isolated major fetal abnormal-
ities were included in the study (i.e.: cardiac or, renal or
cerebral abnormalities of very poor prognosis). All blood
samples were centrifuged for 10 min. at 4000 G at room
temperature and then frozen until assay. We also reviewed
fetal ultrasound profiles during the first trimester and after
if available, fetal karyotyping when it was performed, and
the immediate neonatal outcome. The overall population
was divided into two groups: control pregnancies (n =
7014, pregnancies not associated with any maternal com-
plication at the time of sampling and fetal aneuploidy) and
pregnancies complicated by fetal aneuploidy (n = 96: tri-
somy 21 n = 68, trisomy 18 n = 21, and trisomy 13 n = 7)
from 10WG to 33WG. Among those cases of aneuploidy,
55 cases were fully documented (trisomy 21 n = 31, tri-
somy 18 n = 21, and trisomy 13 n = 3).
Foeto-placental examination and tissue collection
French law allows for the termination of pregnancy with
no gestational age limit when severe fetal abnormalities
are observed. Placenta specimens were collected at the
time of the termination of pregnancy and underwent
macroscopic and microscopic examination. Pathologists
analysed aneuploid placentas in 55 aneuploid cases at
both the macroscopic level (i.e.: hypotrophy, immaturity,
sponginess, hydropsy/ oedema, single umbilical artery),
and histological level (principally hydropic villi, imma-
ture villi, post-mature villi, calcifications, fibrin deposits,
trophoblastic cysts, bullous dystrophy) after being fixed in
formalin, included in paraffin and stained with hematein-
eosin-saffron. Each item was graded (0 if absent, 1 if
present, 2 if abundant) in order to establish a histological
score. We were able to isolate villous cytotrophoblasts
from fresh placentas for in vitro culture in three cases: one
of trisomy 21 at 20 WG, one of trisomy 18 at 19WG and
one of trisomy 13 at 18WG, and three gestational age-
matched controls. Gestational age was confirmed by ultra-
sound measurement of the crown-rump length at 8–12
WG. Trisomy 21, 18 and 13 were diagnosed by karyotyp-
ing chorionic villi, amniotic fluid cells or fetal blood cells.
In no case was aneuploidy due to translocation, and no
mosaicism was observed.
Cell cultures
Cytotrophoblast cells were isolated after trypsin-Dnase I
digestion and discontinuous Percoll gradient fraction-
ation, as described by Kliman but with slight modifi-
cations [17,18]. Briefly, the villous sample was subjected
to sequential enzymatic digestion in a solution con-
taining 0.5% trypsin powder (W/V, Difco), 5 IU/ml
DNAseI, 25 mM HEPES, 4.2 mM MgSO4 and 1% (W/V)









Cystic hygromata 2 3 0
Enlarged NT (≥3.5 mm) 14 9 0
Hydrops 0 1 0
Cardiac abnormalities 0 2 1
Encephalocele 0 2 0
Spina bifida 0 2 0
Exomphalos 0 5 1
2d and 3d trimester
Choroid plexus cysts 1 2 0
Other brain abnormalities 1 0 1
Skull and face abnormalities 1 1 0
Cardiac abnormalities 3 2 1
Digestive atresia 1 1 0
Hepatic calcifications 1 0 0
Renal abnormalities 0 1 0
Ascite 0 1 0
Extremities abormalities 1 1 1
Short femur 1 1 0
Macrosomia or hypotrophia 1 1 0
Fetal death 0 1 0
Decrease or increased amniotic
fluid volume
4 2 1
Ultrasound scanning was performed by experimented operators at the first,
the second and the third trimester on 55 fetuses which were thereafter
diagnosed trisomic 21, trisomic 18 and trisomic 13 diagnosed by karyotyping
chorionc villi, amniotic fluid cells or fetal blood cells.
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with monitoring by light microscopy. The first digest,
and in some cases the second digest, were discarded
on the basis of the light microscopy findings, in order
to eliminate any syncytiotrophoblast fragments. The
cells contained in the four or five subsequent digests
were purified on a discontinuous Percoll gradient (5%
to 70% in 5% steps). Cells that sedimented in the mid-
dle layer (density 1.048-1.062 g/ml) were further puri-
fied using a monoclonal anti-human leukocytic antigen
A, B and C antibody (W6-32HL, Sera Lab, Crawley
Down, UK). W6-32HL negative cytotrophoblast cells were
diluted to a final density of 0.5x106/ml in Dulbecco's
modified Eagle's medium (DMEM) containing 10% foetal
calf serum (FCS). After 4 hours of incubation at 37°C
under 5% CO2, non-adherent cells and syncytial fragments
were removed by three efficient washes in culture
medium. After 3 hours of culture, 95% of cells isolated
from full-term placentas were cytotrophoblastic cells, as
shown by positive cytokeratin 7 staining with a specific
monoclonal antibody (dilution 1:200, Dako). The cells
were further cultured in 2 ml of DMEM supplemented
with 25 mM HEPES, 2 mM glutamine, 10% heat-
inactivated FCS and antibiotics (100 IU/ml penicillin and
100 mg/ml streptomycin) at 37°C under humidified 5%
CO2-95% air. The culture supernatants of aneuploid vil-
lous cytotrophoblasts were then integrated in the placental
physiopole collections operated by the Perinatcollection
project (ANR).
PAPP-A assay
PAPP-A concentrations in the maternal serum and cul-
ture medium were determined using the Immulite 2000
xpi automated chemiluminescent analyser® (Siemens,
Germany) [16]. The IMMULITE 2000 PAPP-A assay is a
solid–phase enzyme-labelled chemiluminescent immu-
nometric assay that uses two monoclonal mouse anti-
PAPP-A antibodies. This assay was first standardized
against the Brahms Kryptor PAPP-A assay. Its analytical
sensitivity was 0.025 mU/ml; the within- and between-
run coefficients of variation were below 4% and 12%,
respectively, and the calibration range was 0–10 mU/ml.
Total hCG was also measured in culture medium as
an index for formation of the endocrine syncytiotro-
phoblast using an Advia Centaur XP analyser® (Siemens,
Germany).
Data analyses
Statistical analysis were performed using the Statview
F-4.5 software package® (Abacus Concepts, Inc., Berkeley,
CA, USA). Values are expressed as crude values and
10ciles, 50ciles, 90ciles values. Significant differences
(p < 0.05) were identified using the non parametric Kruskal-
Wallis and Mann–Whitney U tests.Results
Ultrasound scanning characteristics of fetal aneuploidies
In the 55 cases fully documented, ultrasound scanning is
informative from the first trimester, particularly in tri-
somy 18 (17/21; 81%) (see Additional file 1, Table 1).
Around one third of the trisomic 18 fetuses presented at
least two associated abnormal signs at ultrasound scan-
ning. The most frequent signs were enlarged nt, exompha-
los and cystic hygroma. Other signs tend to become
detectable during the second and third trimesters of preg-
nancy, mainly in the case of Trisomy 21 even if there were
not particularly associated with any type of aneuploidy.
Maternal serum PAPP-A levels during the course
of pregnancy
PAPP-A levels rise throughout a normal gestation from
2.3 mU/mL at 10WG to 56 mU/ml at 24WG and reaches
103 mU/mL at 33WG (Figure 1). There is a sharp, 24-fold
increase (p = 0.01) between the end of the first trimester
Figure 1 Maternal serum levels of PAPP-A throughout normal
gestation and in gestations complicated by fetal aneuploidy.
PAPP-A was measured using the assay developed on the Immulite
2000 analyser (Siemens, Germany) specific for the heterotetrameric
complex (htPAPP-A) in the maternal serum of 7014 normal pregnancies
(controls) and 96 pregnancies affected by fetal trisomy (68 trisomy 21,
21 trisomy 18, 7 trisomy 13) from 10WG to 33WG. Results are expressed
in median values, and 10-90ciles for the controls.
Leguy et al. Reproductive Biology and Endocrinology 2014, 12:129 Page 4 of 8
http://www.rbej.com/content/12/1/129and the end of the second trimester, followed by a slower,
2-fold increase from the end of the second trimester until
delivery. In trisomy 21 PAPP-A levels compared with the
controls were significantly decreased at the end of the first
trimester (median value: 2.7 mU/mL, p = 0.02 ) but not
thereafter (45.8 mU/mL at the end of the second trimester
and 120 mU/mL near the term). In trisomy 18 and trisomy
13, maternal PAPP-A levels were always significantly lower
(p < 0.01 and p = 0.02 respectively) than in the controls
whatever the gestational age. PAPP-A levels were particu-
larly low in trisomy 18 (median value: 0.9 mU/mL at the
end of the first trimester, 9.7 mU/mL at the end of the sec-
ond trimester and 67.7 mU/mL near the term)
In Vitro secretion of PAPP-A and hCG by villous
trophoblastic tissue
We measured the PAPP-A and total hCG secreted
in vitro by villous cytotrophoblasts during their differen-
tiation into syncytiotrophoblast. In the controls, PAPP-A
and hCG levels increased concomitantly with the forma-
tion of syncytiotrophoblast from 24 to 72 hours of cul-
ture, by 10 and 20-fold respectively. hCG secretion was
significantly decreased in trisomy 18 and to a lesser
extent in trisomy 21 but not in trisomy 13. The secre-
tion of PAPP-A was significantly very low (<1 mU/mL,
p = 0.01) in the context of any aneuploidy, with no increase
during the culture (Figure 2).
Placental histology
Investigations were performed in 55 patients (see
Additional file 2, Table 2). Although it was inconsistent,the placenta was macroscopycally rather small (28/55, 51%)
and abnormal (44/55, 80%). In trisomy 21 and trisomy
18, it presented an abnormal mesenchymal core and
abnormal trophoblastic tissue when compared to age
matched controls (Figure 3). Indeed, the placental villi
displayed an important immaturity (26/55, 47%) with an
increased mean villous diameter and stromal hydrops; a
reduction in the number of vessels; a trophoblastic tissue
irregular associating a hypoplasic syncytium with a per-
sisting double layer of villous cytotrophoblasts. These
cytotrophoblasts were lying on frequent fibrin deposits
(16/55, 29%), calcifications (10/55, 18%), hydropic areas
(49/55, 89%) and basophil infiltrates. Hydropic villi and
calcifications were also observed in trisomy 13. A single
umbilical artery and of trophoblastic cysts were only
noted in the context of trisomy 18 whereas bullous dys-
trophy was only noted in the context of trisomy 21. No
abnormality was specific of trisomy 13. The median histo-
logical scores were 6 for Trisomy 21 and 5 for Trisomy 18
(data not shown).
Discussion
This work confirms the value of combining an early de-
termination of maternal serum markers such as PAPP-A
with prenatal ultrasound scanning in order to detect
fetal aneuploidy [19-21]. Indeed, phenotypic abnormal-
ities exist in both trisomic fetuses and the placenta
[22,23]. The anatomical differences between the controls
and trisomic patients are significant enough to be detected
in vivo using prenatal ultrasound scans. Post-mortem ex-
aminations of affected fetuses have confirmed such differ-
ences [24].
As expected, during the first trimester, a common fea-
ture of many chromosomal defects is increased nuchal
translucency [25]. However, our work has shown that
each chromosomal defect tended to have its own syn-
dromic pattern of abnormalities that affect the skull and
brain, the face and neck, the chest, abdomen and ex-
tremities [26].
Although ultrasound scans can demonstrate that major
chromosomal defects are often associated with multiple
fetal abnormalities, maternal serum markers may provide
valuable additional information [26]. We confirm here in a
large cohort that fetal aneuploidies, are generally associ-
ated with decreased PAPP-A levels in maternal serum
[27-29]. This reduction was limited to the first trimester of
pregnancy in trisomy 21 where as it became significative
in the second half of pregnancy in case of trisomy 13. We
were able to establish that it persists throught the gesta-
tion in trisomy 18. These biochemical profiles did not ap-
pear to be linked to any specific histological lesions
affecting the placenta. The present study has thus con-
firmed that in a context of aneuploidy, the villi are mainly
immature, hydropic and poorly vascularised, with fibrin
Figure 2 In vitro secretion of PAPP-A and hCG by villous trophoblast tissues isolated from normal placentas and placentas complicated
by aneuploidy. Villous cytototrophoblasts were cultured after being isolated from aneuploid placentas (one trisomy 21 at 20 WG, one trisomy 18
at 19WG, one trisomy 13 at 18WG) and from three age matched normal placentas. PAPP-A was measured in the culture supernatant from 24 hours
to 72 hours of culture using the assay developed on the Immulite 2000 analyser® (Siemens, Germany) specific for the heterotetrameric complex
(htPAPP-A). hCG was measured with the assay developed on Advia Centaur XP analyser® (Siemens, Germany) to assess the formation of
the syncytiotrophoblast.
Table 2 Principal macroscopic and microscopic findings








Hypotrophy 16 12 0
Immaturity 24 14 0
Sponginess 20 10 0
Hydropsy 24 20 0
Single umbilical artery 0 4 0
Histology
Hydropic villi 28 19 2
Immature villi 20 6 0
Post-mature villi 12 6 0
Calcifications 4 4 2
Fibrin deposits 12 4 0
Trophoblastic cysts 0 4 0
Bullous dystrophy 8 0 0
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blastic tissue is poorly developed with a thin syncytiotro-
phoblast and the persistence of a double layer of villous
cytotrophoblasts. The patterns of trisomic placental villi is
known to change between the first and second trimesters
of pregnancy. During the second trimester, trisomic villi
were predominantly large, irregular and hypovascular,
while during the third trimester, this type of villus abnor-
mality was only observed in a few villi and was associated
with focal hypervascularity.
It is likely that the decrease in PAPP-A levels is not
directly related to the chromosomal defect because the
PAPP-A gene is located on human chromosome 9 and
not on chromosomes 21, 18 or 13. The protein is se-
creted as an active dPAPP-A homodimer in the form of
a metalloproteinase which both interacts with the extra-
cellular matrix and cleaves IGFBP-4 and 5, thus increas-
ing the local bioavailability of IGFs [2-4,8,35-38]. It has
different features that allows PAPP-A to interact with
laminin, complement and heparin sulphates on the cell
Figure 3 Microscopic analysis of placental villi in normal pregnancy and pregnancy complicated by aneuploidy. After termination of
pregnancy, 55 aneuploid placentae were analysed by experimented pathologists at the macroscopic level, and the histological level after being
fixed in formalin, included in paraffin and stained with hematein-eosin-saffron. Mature villi i.e. small diameter, strong staining, presence of fetal
vessels, decreased connective tissue, covered by trophoblastic tissue. Immature hydropic villi i.e. large diameter, pale staining, few fetal vessels,
connective tissue, decreased trophoblastic tissue.
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nancy, almost all circulating PAPP-A is bound covalently
to a glycoprotein, proMBP (preform of eosinophil major
basic protein) to form a hetero-tetrameric complex com-
posed of two PAPP-A and two proMBP subunits
[39]. We were able to establish the maternal profile of
htPAPP-A first using antibodies specific to this complex,
and second not only during the first trimester but also
during the second and third trimesters. We confirmed the
sharp increase of PAPP-A during the first half of preg-
nancy, which has been suggested to reflect the increase in
placental volume, and we showed that the slope of this in-
crease rose very slowly during the second half of preg-
nancy [40-42]. However, very little is known as yet about
the individual secretion profiles of dPAPP-A and proMBP
[43]. The latter is believed to occupy the cell-surface bind-
ing site of PAPP-A in the circulating complex, so that
the tetramer can't bind to the cell surface when it enters
the maternal circulation. dPAPP-A and proMBP, and the
htPAPPA heterotetrameric complex are expressed physio-
logically in the villous trophoblast of the first and third tri-
mesters [4,44-47]. dPAPP-A is weakly expressed in the ST
at full-term, whereas htPAPP-A displays the opposite pat-
tern. We had previously explored the pattern of PAPP-A
secretion by the villous trophoblast in vitro, showing thatthis secretion increased in line with formation of the
endocrine syncytiotrophoblast [48]. During the present
study, we investigated the pattern of PAPP-A secretion by
the aneuploid villous trophoblast. Our preliminary results
suggest that in the case of aneuploidy, the villous tropho-
blast secretion of PAPP-A was altered. In the case of tri-
somy 18, we observed an in vitro decrease in hCG and
PAPP-A secretion, and in vivo a small placental mass and
syncytial mass. We also established in vivo that in trisomy
18, decreased maternal serum PAPP-A levels were not re-
stricted to the first part of pregnancy. Thus, low maternal
PAPP-A levels levels are likely to reflect both a reduction
in placental volume and lower levels of trophoblastic se-
cretion [49-51]. In trisomy 13, as the placental mass is
normal, we can speculate that the decreased maternal
serum PAPP-A levels we observed all along the pregnancy
result predominantly from a defective trophoblastic pro-
duction. In trisomy 21, we confirmed our previous in vitro
findings regarding defective differenciation of villous cyto-
trophoblasts into a syncytiotrophoblast [52]. This led to
the decreased PAPPA secretion we observed. However, we
confirmed that in vivo, maternal serum PAPP-A levels
were decreased but only in the first trimester of preg-
nancy. Thus, the mechanisms involved may be more com-
plex and may differ from one aneuploidy to another [53].
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an impairment of satisfactory differentiation of the vil-
lous cytotrophoblast but also of the extravillous cytotro-
phoblast Indeed, because the decrease in PAPP-A levels
is observed early in any pregnancy associated to fetal an-
euploidy, the defect may concern the extravillous cyto-
trophoblast, which is the principal source of PAPP-A
at this stage. We had previously demonstrated in vitro
changes to the patterns of PAPP-A secretion, to their
regulation during normal gestation and to the tropho-
blastic phenotype, i.e. villous cytotrophoblast or extra-
villous cytotrophoblast [54]. Further studies are now
necessary to focus on aneuploid extravillous cytotro-
phoblasts, but some findings have suggested defective
differentiation along the invasive pathway that can affect
not only PAPP-A but also other proteases (i.e. MM-9,
ADAM12) [55,56]. This could explain why these proteases
have been proposed as biomarkers of aneuploidy [57]. It is
likely that not only the trophoblastic cells but all cells in
the villi could turned over and be differentially modified in
the context of aneuploidy [30,58,59].
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